scout
|Videos|June 16, 2016

Potential Impact of Regorafenib in Patients With HCC

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME